Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
Tour our lab
Our flagship assay NeXT Personal®, can detect recurrence before scans, showing evidence of tumors as much as ~3 years earlier in some cases.5
Our tests can identify the subtlest signs of cancer, detecting as little as about one fragment of cancer DNA among a million healthy DNA fragments.
We do this by combining advanced cancer genomics with analytics to harness the uniqueness of each patient’s tumor through personalized testing.
Our next-generation technology enables your care team to detect changes in your cancer sooner, and develop personalized treatment strategies to stay ahead of cancer.
NeXT Personal® delivers ultra-sensitive test results to oncology care teams.
Our advanced NeXT Personal test detected up to 4X as many patients with disease as previous generation assays in a hard-to-detect cancer (lung adenocarcinoma).1
The care team relies on accurate disease information to make timely decisions after curative intent treatment: Is the treatment working? Does the patient need more therapy? Is the cancer all gone? Is the cancer likely to return? That is why sensitivity matters.
Only an ultra-sensitive test can detect ultra-low traces of cancer early on and help the team anticipate next steps. NeXT Personal test identified disease recurrence and relapse multiple months before scans.1, 5, 6
Our personalized blood test helps you determine ahead of scans: if your treatment is working, if your cancer is still there after treatment, and if your cancer is likely to come back.1,5,6
Our advanced tumor profiling test looks at all of the genes in your cancer cells to help match effective targeted treatments specific to your cancer.
Our innovative biomarker analysis platform provides the backbone for development of personalized cancer vaccines and other targeted treatments.
Personalis is revolutionizing cancer care with combined expertise in advanced testing, cancer genomics, and data science. Partner with us to unlock the potential of personalized treatments, drive groundbreaking innovations and better patient outcomes.
Year Founded
Sq ft Lab & Office Facility
Human Samples Sequenced
Biopharma Partners
Publications & Posters
Issued Patents
QMS & Regulatory Credentials | ISO13485-2016
The NeXT Platform will be used in clinical studies evaluating mRNA-4157/V940, an investigational individualized neoantigen therapy.
An ultra-sensitive and specific ctDNA assay provided novel pre-operative disease stratification in early stage lung cancer.
Corporate headquarters expansion (100,000 square foot facility) to accelerate growth in laboratory operations and research & development.
PRO-1090-v5
